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Abstract
Background TheMagenstrasse andMill (M&M) procedure is
a vertical gastroplasty creating a tubular pouch extending from
the cardia to the antrum. This “incomplete sleeve” avoids
gastric resection or band placement. In this paper, we report
our experience of the laparoscopic approach of the technique
in a selected obese population excluding prominent grazer
and/or sweet eaters.
Material and Methods One hundred patients (39 males, 61
females) underwent the procedure in a prospective trial. Mean
age was 40 years (range 18–68). Mean preoperative BMI was
43.2 kg/m2 (range 35–62).
Results The procedure was performed by laparoscopy starting
with the creation of a circular opening at the junction of
antrum and corpus followed by a vertical stapling to the angle
of Hiss. Mean duration of the procedure was 67 (range 40–
122) min. No intraoperative complication occurred. Mean
hospital stay (SD) was 2.5 (0.9) days. The single postoperative
complication consisted in a mild stenosis that responded
to endoscopic dilatation. After a mean follow-up of
15 months (range 9–24), mean percentage of excess
body weight loss (SD) was 48(14), 59(18) and 68(24)%,
respectively at 3, 6, and 12 months. Quality of life ap-
peared satisfactory with a low incidence of gastroesoph-
ageal reflux. The procedure was associated with improve-
ment or resolution of diabetes, arterial hypertension, and
dyslipemia at 1 year.
Conclusions Our experience demonstrated that the M&M
procedure could be performed safely laparoscopically. The
satisfactory results on weight loss, obesity-associated
mordities, and quality of life will need to be confirmed on
longer follow-up.
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Introduction
Bariatric surgery has evolved for over 50 years to an accepted
and only long-term treatment of morbid obesity.
Malabsorptive techniques used in the early days were associ-
ated with severe gastrointestinal and hydroelectrolytic distur-
bances that led bariatric surgeons to adopt Roux-en-Y gastric
bypass (RYGB) as a reference procedure in term of weight
loss and treatment of obesity comorbidities with low morbid-
ity and mortality [1]. The technique is however demanding,
particularly for the laparoscopic procedure. The long-term
complications associated with the technique include marginal
gastrojejunal ulcers (5–16 %) [2] and bowel obstruction sec-
ondary to internal hernia or adhesions [3]. It also imposes
monitoring of minerals and vitamins, whose absorption is
decreased by the bypass of the proximal intestine. Finally,
the difficulties to assess the excluded stomach and to explore
the biliary tract are also drawbacks of the technique. In series
excluding sweet eaters and/or super obese patients, the gastric
bypass did not prove superior to restrictive surgery (82 vs
80 % excess weight loss (EWL) at 2 years) but resulted in a
higher complication rate [4, 5].
Vertical banded gastroplasty demonstrated good results on
weight loss and its related metabolic complications [6, 7]. The
technique suffered however from two major complications:
disruption of the staple line (8–48%) and problems associated
with the band used to limit the expansion of the pouch outlet
with stenosis (4–21 %) or transgastric migration [8]. The
adjustable band gastroplasty took over in the 1990s because
of the easier laparoscopic placement and satisfying results on
weight loss. However, this technique also led to failures
secondary to band slippage, pouch dilatation, band erosion,
or food intolerance [9].
More recently, the sleeve gastrectomy (SG) initially pro-
posed as a first step procedure gained rapid acceptance be-
cause it is technically less demanding than RYGB with satis-
fying short- and intermediate-term results on weight loss
(56.1 % EWL at 1 year, range 49–81 %) [10, 11] and on
resolution of obesity-associated comorbidities [12]. The SG
furthermore avoided the complications related to banded
gastroplasties that shadowed the 50–60 % EWL at 10 years
reported in selected populations [6–8]. Those aspects ex-
plained that many surgeons chose to perform SG despite its
irreversibility and a postoperative complication rate (10–
13 %) similar to RYGB [10, 13].
Prospective Study of Laparoscopic Magenstrasse and Mill
Procedure
Based on those considerations, we decided to re-evaluate the
Magenstrasse and Mill (M&M) procedure (Fig. 1) described
by Johnston et al. in 1987 [14]. This ancestor of the SG
potentially combined the advantages of the restrictive
procedures described above without resection or band place-
ment and their associated complications. After the creation of
a circular opening in the stomach at the junction between the
corpus and the antrum, the stapling progressed along the small
gastric curvature to create a tubular pouch similar to a sleeve
but preserved a channel allowing the greater stomach to empty
in the antrum.
Material and Methods
The laparoscopic approach of the procedure was evaluated in
the Department of Abdominal Surgery of the CHU of Liège in
a prospective study after approval of the local ethical commit-
tee (NCT02050477). The primary end points were the evalu-
ation of the procedure on surgical morbidity and mortality and
on weight loss.
All patients were assessed by a multidisciplinary team
specialized in bariatric and metabolic surgery including sur-
geon, endocrinologist, psychologist and/or psychiatrist,
dietetician. Their alimentary behavior (especially their ability
to avoid interprandial feeding) was characterized after dietetic




& BMI>35 with diabetes or sleep apnea syndrome or hy-
pertension treated with three drugs for at least 1 year
& Male or female patients between 18 and 75 years of age;
fertile female patients must use a reliable contraception
method;
& No previous bariatric procedure
& Informed consent given by patient
Exclusion Criteria
& Medical contraindication for a general anesthesia or ab-
dominal surgery (allergies to anesthetic drugs, cardiovas-
cular, pulmonary, or renal conditions leading to an unac-
ceptable risk for the procedure)
& Psychological-psychiatric (boulimia, severe depression,
psychotic condition)
& Non-stabilized endocrine disorder, with potential interfer-
ence on weight and/or diabetic condition
& Inability to understand goal of the study, plan of treatment,
and follow-up
& Large hiatal hernia and/or severe esophageal reflux
disease
& Prominent grazer and/or sweet eater behavior
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Preoperative Workup
Preoperative workup included an upper GI endoscopy. Sys-
tematic preoperative research of Helicobacter pylori infection
was carried out and treatment given if necessary with pump
proton inhibitors (PPIs) 40 mg per os by day, amoxicillin 1 g
per os twice a day, and clarithromycin 500 mg per os twice a
day for 1 week. Eradication was controlled by endoscopy or
by an urea breath test between 4 and 8 weeks after the end of
treatment. All patients underwent an abdominal ultrasound.
Prophylactic cholecystectomy was proposed to each patient
when gallstones were detected.
Anesthesia
Patient received alprazolam 0.5 mg, ranitidine 300 mg, and
domperidone 1 h prior anesthesia. After positionning in
ramping position and set up of the standard baseline monitor-
ing, patients were preoxygenated with continuous positive
airway pressure (CPAP) 10 cm H2O with FIO2=1 until
FeO2 reaches 0.90. A rapid sequence induction was then
performed with sufentanil 15 mcg, lidocaïne 1 mg/kg, titrated
propofol, and succinylcholine 1 mg/kg. Anesthesia was main-
tained with inhalated desflurane titrated on BIS monitoring,
and deep muscle relaxation was achieved with repeated
rocuronium boli. Lungs were ventilated using volume-
controlled ventilation, a 10 cm H2O PEEP, and with a mixture
of air-oxygen (FIO2 0.8). Ventilation was set to maintain an
ETCO2 under 45. A single dose of IV cephazoline was given
prior to incision. Before the end of the surgery, patients were
given IV paracetamol 2 g, tramadol 100 mg and if no contra-
indication, IV parecoxib 80 mg to provide efficient pain relief.
To limit the incidence of postoperative nausea and/or
vomiting, our anesthesia protocol avoided the use of intraop-
erative nitrous oxide and included the intravenous administra-
tion of dexamethasone 5 mg at the time of induction,
droperidol 0.625 mg at the end of surgery, and ondansetron
4 mg postoperatively as needed.
Surgical Technique
The patient was placed in a supine position, split leg with
reverse Trendelenburg position. Initial access was obtained by
means of a Veress needle technique at the left anterior
subcostal area. Carbon dioxide pneumoperitoneum was
established to a pressure of 14 mm Hg. A 0° angle scope
was used. Five ports were inserted (Fig. 2).
In the first part of the procedure, the laparoscope was
placed in the lower port in the midline. After retraction of
the stomach, the procedure started by the incision of the
greater omentum below the antrum, preserving the
gastroepiploic vessels attached to the greater curvature of the
stomach to enter the lesser omental bursa. Posterior gastric
adhesions were divided toward the left crux of the diaphragm.
A marking with the cautery was performed on the
anterior surface of the stomach at the junction of the
corpus and antrum, halfway between the lesser and great-
er curvatures at the level of the angularis incisura. Care
was taken to avoid damage to the vagal branches of the
crow’s foot innervating the antropyloric region. A “mir-
ror” marking was done on the posterior wall of the
stomach.
The sharp tip of the anvil of an endoscopic curved
intraluminal stapler (ECS21A, 21 mm, Ethicon Endosurgery,
Cincinnati, USA) was pushed through the wall of the stomach
from the posterior mark toward the anterior (Fig. 3).The use of
an adapted “anvil holder” (Metal Instrument Head Forceps,
Ethicon Endosurgery, Cincinnati, USA) was mandatory to
perform the latter step precisely. After removal of the sharp
Fig. 1 The Magenstrasse and Mill procedure
Fig. 2 Ports placement
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tip of the anvil, the anvil was connected to the instrument and
the ECS was fired creating a circular opening (Fig. 4).
The laparoscope was then placed in the 11 mm port in the
epigastric area. An orogastric calibration tube (50 Fr) was
advanced through the stomach alongside the smaller curvature
and on the right side of the previously made circular stapling.
We fired five to six 60 mm cartridges (Echelon 60, Ethicon
Endosurgery, Cincinnati, USA) from the circular opening
tightly along the calibration tube toward the angle of Hiss
(Fig. 5). The height of the staples were adapted to the thick-
ness of the gastric wall, the first one or two being 3.8 mm
cartridges while the others were 3.5 mm ones.
Any bleeding from the staple lines was controlled with the
cautery. A running suture of Maxon 3/0 V-Loc (Covidien,
Mansfield, USA) was used to reinforce the staple line from
the circular stapler as it has only two rows of staples.
A 21 Fr silicone drain was left between the divided parts of
the stomach.
Follow-up
To prevent deep venous thrombosis, patients received a daily
subcutaneous injection with low-molecular-weight heparin
for 20 days postoperatively. PPIs were prescribed for 1 month.
A multivitamin complex (Omnibionta Pronatal, Merck,
Darmstadt, Germany) was prescribed for 6 months.
The patients had a clinical follow-up by the multidisciplin-
ary team at 1, 3, 6, 12, and 24months after surgery then yearly.
A systematic evaluation reported any complaints (incl. inci-
dence of GERD) by the patient, changes in obesity-associated
morbidities and in medications. A comprehensive blood work
including carbohydrate metabolism and lipid profile, minerals
and vitamins was done at 3, 6, 12, and 24 months.
Results
Surgical Procedure and Postoperative Evolution
One hundred patients (61 F/39 M) underwent the procedure
with a mean follow-up of 16 months (range 10–24). Mean age
was 40 (range 18–68) years. Mean preoperative weight and
BMI were respectively 124 kg (range 90–196) and 43.2 kg/m2
(range 35–62). Associated comorbidities are shown in
Table 1.
Mean operative time (SD) was 71(27) min for the entire
group. Excluding those with an associated procedure (chole-
cystectomy or previous abdominal surgery with peritoneal
adhesions), mean duration of surgery was 67 min (range 40–
122). No intraoperative complication occurred.
On postoperative day 1, an upper GI opacification was
done. No leak or other complication was evidenced. Drain
and intravenous infusions were removed on postoperative day
1, and a liquid diet was started and progressed on day 2 to a
solid diet. One patient complained of solid dysphagia from
day 2. Only a mild stenosis at the lower part of the pouch was
evidenced. He had to undergo two endoscopic dilatations on
Fig. 3 Positioning of the sharp tip of the anvil after opening of the
gastrocolic ligament
Fig. 4 Circular stapling preserving the vagal branches of the crow’s foot
Fig. 5 Linear stapling from the circular opening toward Hiss angle
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weeks 3 and 4 with parallel dietetic counseling. The problem
resolved after 6 weeks.
Mean (SD) duration of hospital stay was 2.5(0.9) days.
At follow-up, the patients reported no undesirable symp-
toms except for a few episodes of postprandial dysphagia.
Those were present in the early postoperative period associ-
ated with the change in eating behavior imposed by the
restrictive surgery. Incidence of esophageal reflux symptoms
was 11 % before surgery and 10, 7, and 14 %, respectively at
3, 6, and 12 months postoperatively. Symptomatology was
mild, intermittent, and easily controlled with PPIs.
Evolution of Weight Loss
Mean weight (SD) decreased from 124(21) kg to 100(19),
94(19), and 89(20) kg respectively at 3, 6, and 12 months after
surgery. Mean percentage of excess body weight loss (SD) was
47(14), 59(18), and 68(24)% at the same time points (Fig. 6).
Evolution of Obesity-Associated Morbidities
Four out of five diabetic patients on oral antidiabetic drugs
could stop their medications at 1 year. The treatment of the
fifth patient was decreased from bitherapy to monotherapy.
Mean HBA1c level of those five patients decreased during the
same period from 6.6 (range 5.7–7.9) to 5.7 % (range 5–6.1)
(p<0.05). Four out of our nine insulin-dependent type 2
diabetic patients could stop their insulin treatment after 1 year,
two of them still being on oral antidiabetic drugs. The remain-
ing six insulin dependent patients (including one patient with
type 1 diabetes) could reduce their daily insulin dose to amean
39 % of the initial dose (p<0.05). HBA1c levels of the group
preoperatively on insulin decreased from 8.2 to 7 % at 1 year
(p=0.07) while their treatment was decreased or stopped.
From 27 patients on hypertensive drugs before surgery for
whom we had data at this point of follow-up, 7 (26 %) were
able to discontinue their treatment at 1 year. Dyslipemia also
improved. We had complete preoperative and 1-year postop-
erative blood lipid profile from 50 preoperatively dyslipemic
patients. Forty-two percent of the patients with initial choles-
terol and/or triglyceride levels above normal range (cholester-
ol >1.9 g/l and triglycerides >1.5 g/dl) normalized their levels
at 1 year. Eight out of 16 patients on lipid-lowering treatment
could stop their medication. While mean cholesterol level did
not decrease significantly considering the entire dyslipemic
group (2.07 preoperatively vs 1.97 at 1 year, p=0.07), the
difference reached significance considering dyslipemic pa-
tients without initial treatment (2.13 vs 1.97, p<0.05) by the
exclusion of the effect of lipid-lowering medication suppres-
sion. The decrease was significant for mean triglyceride levels
in both groups, with mean values decreasing from 1.57 to 1.1
(p<0.05) and from 1.60 to 1.08 (p<0.05).
Clinical sleep apnea syndrome disappeared at 1 year in 9
out of 17 patients (53 %) for whom we had data at the time of
analysis. From the latter group, three out of six preoperatively
on CPAP could stop their treatment.
Evolution of Blood Vitamins and Minerals
Mean preoperative vitamin D levels were below normal range
in 92% of our population. A supplementation was given to the
latter patients that led to a significant increase of its blood level
at 1 year, remaining however below normal range. All other
vitamins and mineral mean blood levels at 3, 6, and 12months
remained within normal range within the current follow-up.
Levels of folic acid and vitamin B12 were however signifi-
cantly higher than preoperative values after 3 and 6 months
(and after 12 months for folic acid) postoperatively due to the
prophylactic supplementation. Levels of iron, vitamin A, and
Fig. 6 Weight loss evolution after laparoscopic M&M over a 12-month
period. The number of patients (Pts) at 1, 3, 6, and 12months follow-up is
shown below the x-axis
Table 1 Associated comorbidities
Obesity-associated morbidities %
Diabetes 18
On insulin (incl. one type 1 diabetic) 10





Sleep apnea syndrome 21
On CPAP 8
Cardiac failure 1
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vitamin E remained stable while a slight decrease of zinc
levels was observed at 1 year.
Discussion
Reports of the M&M procedure consisted mainly of the
studies of the original series. The Johnston group [14] reported
a series of 100 patients operated between 1992 and 1998 with
a mean preoperative BMI of 46.3 kg/m2. Their mortality was
0 %, and major complications occurred in 4 % of patients.
These included a tear at the junction between the left
suprahepatic vein and the IVC, a fistula from the proximal
end of the Magenstrasse and two from the excluded gastric
fundus. Meanweight loss was 38(14) kg equivalent to 60% of
excess weight, obtained within 1 year of operation and main-
tained for 3 years [15].
Our laparoscopic series was associated with a low compli-
cation rate. Our experience with laparoscopic RYGB probably
played a role in the learning curve with the technique. Our
mean operative time favorably compared to the surgery dura-
tion of laparoscopic SG (average 100 min) in a systematic
review [16]. The crucial part was the correct positioning of the
circular stapling to avoid gastric stenosis on any side. The
division of all adhesions between the posterior aspect of the
stomach, and the pancreas were also mandatory to perform a
regular tubular pouch. The procedure itself avoids any high-
pressure zone distally to the gastric tube with the preservation
of the antrum motricity (dependent of the avoidance of vagus
nerve lesion) that could decrease the risk of staple line dehis-
cence compared to a sleeve.
At this point of follow-up, the clinical results of the lapa-
roscopic M&M compares favorably to other bariatric tech-
niques with 68 % EWL at 1 year. The reduced sensation of
hunger after the procedure seemed to play a major role,
property shared with gastric bypass or sleeve gastrectomy.
The side effects of the procedure appeared mild with a low
incidence of dysphagia or gastroesophageal reflux. This good
quality of life thus mirrors the 88 % satisfaction rate of the
study of Carmichael et al. [17]. The role of the multidisciplin-
ary team in the preoperative and postoperative care could also
play a role to explain the low incidence of upper GI symptoms
with a special emphasis on meal fractioning and volume
limitation. We believe that it also participated to the results
obtained so far on weight loss, not only in the selection of
patients (exclusion of predominant grazer and sweet eater
behavior) but also on the preoperative modification of diet
behavior. This might explain the lower results obtained in the
only other laparoscopic report of the procedure in a super
obese population of seven patients [18].
TheM&M technique offers potential advantages compared
to a SG. The preservation of the greater curvature may be
useful in the repair of a fistula or a stricture at the level of the
gastric tube, which in the case of a sleeve can lead to repeated
stent placement or gastrectomy with esojejunal anastomosis
[19, 20]. The absence of gastrectomy avoids dissection of the
gastrosplenic ligament associated to a risk of vascular or
splenic lesions. The more limited surgical trauma could de-
crease the risk of portomesenteric thrombosis reported after
bariatric surgery including sleeve gastrectomy [21, 22]. The
absence of organ to extract limits the parietal trauma. Postop-
erative biological controls in our study confirmed at this point
the absence of vitamins or mineral deficiencies reported by the
Johnston group [23]. Our mean 15-month follow-up and the
use of prophylactic multivitamin complex during the first
6 months limit however the interpretation of our data. The
restrictive nature of the surgery and the absence of gastric
resection that should ensure normal gastric pH and intrinsic
factor production should nevertheless limit the latter risk
observed after SG [24, 25].
The preservation of the gastric fundus and corpus raised
several questions. The concerns about difficulty of greater
stomach part emptying were not encountered in the current
follow-up. Postoperative upper GI opacification demonstrated
in our study preferential emptying in the duodenum with only
partial filling of the fundus. This potential complication was
neither reported in the series from Johnston et al. who reported
no alteration in gastric emptying studies [23]. The removal of
the greater curvature of the stomach in SG is also believed to
explain the results obtained by the latter procedure in terms of
weight loss and improvement of comorbidities by hormonal
modifications. The present study demonstrated an improve-
ment of obesity-associated morbidities. In particular, four out
of five non-insulin-dependent diabetic patients could stop their
medication with a normal HBA1c at 1 year. Only four insulin-
dependent type 2 diabetics out of nine could stop their insulin
treatment. Those nine patients had however a long history of
diabetes with a minimum period on insulin of 10 years except
for one of the two patients currently in remission (5 years
duration of insulin treatment). The limited number of patients
and the absence of control group do not allow us to draw
conclusions but justify future prospective randomized studies.
The reason for which the procedure did not gain wide-
spread recognition and popularity may be related to the lim-
ited report of the technique and the expansion of the laparos-
copy at the same period that led surgeons to choose other
bariatric procedures more easily to translate with the laparo-
scopic instruments available in those early days.
Its durability can only be extrapolated at this time from the
results of the original series [15]. Concerns about its efficacy
that led to investigate variations of the original technique [15,
26] are not supported by literature evidence as large-size long-
term studies are lacking. Many questions remain. We used in
this study a 50 Fr bougie to limit solid food dysphagia and
avoid patient orientation toward a more liquid hypercaloric
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diet. The use of a smaller size bougie might improve long-
term control of weight, as was suggested in the original report
of the M&M [14]. The issue remains controversial in reports
after SG while the price to pay may be a higher postoperative
leak rate [27–29]. It however might be of particular impor-
tance in subsets of patients, such as the super obese population
with the greatest alimentary behavior imbalance reflected by
the negative correlation of BMI and postoperative weight loss
in most studies [30]. The M&M remains in any case a pure
restrictive procedure that requires preoperative patient educa-
tion and selection and postoperative follow-up.
This paper reports, to our knowledge, the largest experi-
ence on laparoscopic M&M. These results suggest that the
laparoscopic M&M procedure could be a first choice tech-
nique for patients that are not prominent grazer or sweet
eaters. The absence of food intolerance or malabsorption
might not position this surgery as a first choice procedure
for part of the super obese population with a severe alimentary
misbehavior. Its role as a first step surgery could however be
considered as the preservation of stomach integrity would
keep open all surgical possibilities in case of failure. Further
studies remain to be done to validate these results on longer
follow-up, define the effects on obesity-related illnesses, and
identify the patient population best helped by this procedure to
position the M&M as a valid alternative to existing laparo-
scopic bariatric techniques.
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